European Journal of Cancer and Clinical Oncology最新文献

{"title":"Interleukin-2 therapy for refractory and relapsing lymphomas","authors":"Jean-Marc Tourani ,&nbsp;Vincent Levy ,&nbsp;Josette Briere ,&nbsp;Rafaël Levy ,&nbsp;Chris Franks ,&nbsp;Jean-Marie Andrieu","doi":"10.1016/0277-5379(91)90444-I","DOIUrl":"10.1016/0277-5379(91)90444-I","url":null,"abstract":"<div><p>Recombinant interleukin-2 (rIL-2) has been reported to be active in metastatic renal cell carcinoma and malignant melanoma. The purpose of this trial was to determine the efficacy and toxicity of rIL-2 administered in continuous infusion in patients with Hodgkin's disease (HD) and non-Hodgkin lymphoma (NHL). 21 patients with HD (4 patients), diffuse large-cell NHL (7) or low-grade NHL (10) in failure or relapse after multiple-conventional treatments were included in this trial. rIL-2 therapy consisted of an induction period of two cycles separated by 3 weeks of rest, and, in the absence of progressive disease or undue toxicity, a maintenance period of 4 monthly cycles. Each induction cycle comprised the continuous infusion of rIL-2: 18 × 10⁶ IU/m² per day on days 1–5 and days 12–16. Each maintenance cycle comprised the continuous infusion of rIL-2: 18 × 10⁶ IU/m² per day on days 1–5. Among the 21 treated patients, 5 (all of those with low-grade NHL) responded to the induction phase (1 complete response, 4 partial responses) and 2 patients had a mixed response. Conversely, no response was observed in patients with HD or large-cell NHL. The median duration of response was 4 months. rIL-2 administered as a continuous infusion was well tolerated and most patients received the full dosage, and management did not require intensive care. During the induction period, 2 patients experienced grade III cardiovascular or renal toxicity. During the maintenance period, rIL-2 had to be interrupted in 1 patient because of a myocardial infarction. This trial confirms the inefficacy of rIL-2 for the treatment of large-cell NHL and HD. Conversely, in low-grade NHL, rIL-2 activity needs to be explored by further studies. rIL-2 may have a place in the early phase of the disease, when the immune system is not compromised, as an adjuvant treatment in residual disease in order to improve the duration of response.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 12","pages":"Pages 1676-1680"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90444-I","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12944439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase II study of combination vincristine, epirubicin and cyclophosphamide in advanced breast cancer in Chinese patients","authors":"W. Shiu,&nbsp;M. Tao,&nbsp;T. Leung","doi":"10.1016/0277-5379(91)90453-K","DOIUrl":"10.1016/0277-5379(91)90453-K","url":null,"abstract":"","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 12","pages":"Page 1710"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90453-K","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12944353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bone marrow transplantation with unrelated volunteer donors","authors":"Gösta Gahrton","doi":"10.1016/0277-5379(91)90407-5","DOIUrl":"10.1016/0277-5379(91)90407-5","url":null,"abstract":"","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 12","pages":"Pages 1537-1539"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90407-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12944006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential c-myc protein expression in Burkitt's lymphomas and EBV-transformed lymphoblastoid lines","authors":"Anders D. Wennborg ,&nbsp;Ender Altiok ,&nbsp;John P. Moore ,&nbsp;Ingemar Ernberg ,&nbsp;George Klein","doi":"10.1016/0277-5379(91)90436-H","DOIUrl":"10.1016/0277-5379(91)90436-H","url":null,"abstract":"<div><p>The levels of c-<em>myc</em> protein expression in three types of Epstein-Barr virus (EBV) transformed human B-cell derived lines were examined with an ELISA assay. Six independently maintained sublines of the same EBV-transformed pro-B-cell line (FLEB-14), six B-cell lines (LCL) and six Burkitt's lymphoma lines (BL) were compared. The average amount of c-<em>myc</em> protein, calculated from at least three independent tests on each line, differed between the three groups. Expressed in relative units, the ratio of the means was 1:2:5 for the LCL:FLEB:BL lines. The differences were statistically significant at <em>P</em> &lt; 0.01.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 12","pages":"Pages 1643-1645"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90436-H","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12944433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Haemodynamic effects of recombinant interleukin-2 administered by constant infusion","authors":"Jeffrey S. Groeger ,&nbsp;Dean Bajorin ,&nbsp;Bonnie Reichman ,&nbsp;Isabelle Kopec ,&nbsp;Omar Atiq ,&nbsp;Mary Kathryn Pierri","doi":"10.1016/0277-5379(91)90426-E","DOIUrl":"10.1016/0277-5379(91)90426-E","url":null,"abstract":"<div><p>Adoptive immunotherapy with recombinant interleukin-2 (rhIL-2) has been reported to induce tumour regression in some patients with refractory cancer. However, the cardiovascular toxicity of bolus therapy requires invasive monitoring of patients in the intensive care unit (ICU). In an effort to examine the haemodynamic alterations caused by a constant infusion of IL-2, as opposed to bolus therapy, we studied the haemodynamic variables of 10 patients, with no evidence of heart disease, receiving 3 × 10⁶ IU/m² per day of rhIL-2 as a continuous infusion for 5 days. Measured and derived haemodynamic variables were obtained immediately prior to, at 2, 24, and 48 h during, and upon termination of the infusion. There was no evidence of clinical haemodynamic instability in these patients. Except for development of fever and tachycardia, there were no clinically significant differences in any measured or derived haemodynamic parameter. Moreover, continuous electrocardiographic monitoring of these patients during the infusion did not reveal any abnormalities. Invasive haemodynamic monitoring in an ICU is not necessary in carefully selected patients receiving constant infusion rhIL-2, at the described dose and schedule.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 12","pages":"Pages 1613-1616"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90426-E","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12945227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alpha interferon in the treatment of mixed cryoglobulinaemia patients","authors":"Clodoveo Ferri ,&nbsp;Emanuele Marzo ,&nbsp;Giovanni Longombardo ,&nbsp;Francesco Lombardini ,&nbsp;Francesco Greco ,&nbsp;Stefano Bombardieri","doi":"10.1016/0277-5379(91)90583-Y","DOIUrl":"10.1016/0277-5379(91)90583-Y","url":null,"abstract":"","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 ","pages":"Pages S81-S82"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90583-Y","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12961548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Several new approaches to improvement of alpha interferon therapy in chronic myelogenous leukaemia","authors":"Shigetaka Asano ,&nbsp;Hiromi Ogura ,&nbsp;Kenzaburo Tani ,&nbsp;Tokiko Inoue ,&nbsp;Arinobu Tojo ,&nbsp;Keiya Ozawa","doi":"10.1016/0277-5379(91)90559-V","DOIUrl":"10.1016/0277-5379(91)90559-V","url":null,"abstract":"<div><p>Several basic experimental and clinical studies were carried out in an attempt to improve the efficacy of alpha interferon therapy for chronic myelogenous leukaemia (CML). First, the combined use of hydroxyurea (HU) and interferon (500–1000 mg daily) in interferon-resistant cases facilitated maintenance of reduced leucocyte production, or a reduction in the dose of interferon, although suppression of Philadelphia chromosome (Ph¹)-positive clones was not observed in most cases. In order to try and decrease the rate of lymphoblastic crisis during the course of interferon therapy, we recently added methotrexate (MTX) (10–15 mg, weekly) to the treatment protocol. Since then, no lymphoblastic crisis has been observed. Second, the <em>in vitro</em> expression of alpha interferon-stimulated gene (ISG) mRNA was shown to be markedly decreased in granulocytes of one representative interferon-resistant case, compared to that in granulocytes of the three interferon-sensitive cases. Interestingly, it was found that the transcriptional activity in this case became almost normal when the blood granulocytes were controlled by the addition of HU. These findings suggest that the <em>in vitro</em> transcriptional assay of ISG mRNA may be clinically useful for predicting alpha interferon efficacy. Third, when genetically manipulated, alpha interferon-producing NIH/3T3 cells were co-transplanted using diffusion chambers into nude mice bearing a CML cell line, KU812, the CML tumour growth was shown to be markedly suppressed. This experimental model for alpha interferon replacement gene therapy suggests some directions for future studies on interferon therapy.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 ","pages":"Pages S21-S25"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90559-V","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12961600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severe mucositis after chemotherapy with vinorelbine, 5-flourouracil, leucovorin and cisplatin","authors":"Isabelle Monnet ,&nbsp;Patrick Chariot ,&nbsp;Nacer Azli ,&nbsp;Pierre Ruffié ,&nbsp;Sabine Voisin ,&nbsp;Jean-Claude Saltiel ,&nbsp;Hubert de Cremoux ,&nbsp;Esteban Cvitkovic","doi":"10.1016/0277-5379(91)90460-U","DOIUrl":"10.1016/0277-5379(91)90460-U","url":null,"abstract":"","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 12","pages":"Pages 1716-1717"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90460-U","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12829925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetics and cancer","authors":"W.K. Cavenee ,&nbsp;B. Ponder ,&nbsp;E. Solomon","doi":"10.1016/0277-5379(91)90451-I","DOIUrl":"10.1016/0277-5379(91)90451-I","url":null,"abstract":"","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 12","pages":"Pages 1706-1707"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90451-I","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12944352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ras p21 expression in relation to DNA ploidy, S-phase fraction and prognosis in colorectal adenocarcinoma","authors":"Xiao-Feng Sun ,&nbsp;Sten Wingren ,&nbsp;John M. Carstensen ,&nbsp;Olle Stål ,&nbsp;Thomas Hatschek ,&nbsp;Bernt Boeryd ,&nbsp;Bo Nordenskjöld ,&nbsp;Hong Zhang","doi":"10.1016/0277-5379(91)90437-I","DOIUrl":"10.1016/0277-5379(91)90437-I","url":null,"abstract":"<div><p><em>ras</em> p21 expression, as indicated by the monoclonal antibody ras 11, was estimated using immunohistochemistry on 69 primary colorectal adenocarcinomas. Also, DNA ploidy and S-phase fraction (SPF) were analysed with flow cytometry. Positive staining for ras 11 tended to be more common in DNA non-diploid tumours (<em>P</em> = 0.11), but was significantly correlated with high SPF (<em>P</em> = 0.038). Positive ras 11 staining, Dukes' stage, DNA ploidy and SPF were related to the recurrence-free interval of patients with Dukes' A–C tumours (<em>P</em> = 0.0014, <em>P</em> = 0.023, <em>P</em> = 0.035 and <em>P</em> = 0.040, respectively). ras 11 staining was a prognostic factor independent of both Dukes' stage and DNA ploidy (<em>P</em> = 0.011). The results indicate that pan <em>ras</em> p21 expression is associated with proliferative activity and has an independent prognostic value in colorectal adenocarcinoma.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 12","pages":"Pages 1646-1649"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90437-I","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12944434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}